OSCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oscar Health Inc (OSCR) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company demonstrates strong growth potential, positive technical indicators, and favorable options sentiment. Despite some uncertainties in its long-term visibility, the company's recent upgrades, growth trajectory, and competitive positioning in the ACA marketplace make it a compelling investment opportunity.
The technical indicators for OSCR are bullish. The MACD histogram is positive and contracting, RSI is neutral at 66.274, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels with resistance at 29.467 and 30.967, indicating potential upward momentum.
Oscar Health projects $19 billion in revenue and $450 million in operating income by
The company has grown its customer base to 3.2 million and aims to double it to 6.5 million in five years, potentially increasing premium revenue to $50 billion.
Free telehealth services and high customer satisfaction provide a competitive edge.
Recent analyst upgrades and increased price targets reflect confidence in the company's growth trajectory.
Analysts note low visibility beyond 2026, particularly regarding risk pool shifts and new geographic growth.
Neutral sentiment from hedge funds and insiders indicates no significant institutional or insider buying activity.
Financial data is unavailable for the latest quarter. However, the company has highlighted strong growth projections, including significant revenue and operating income targets by 2026.
Analyst sentiment has improved, with multiple upgrades and increased price targets. Wells Fargo upgraded the stock to Equal Weight with a price target of $20, citing confidence in the company's exchange market trajectory. Barclays raised its price target to $30, reflecting durable growth post-Q1 results. Other analysts have also raised their targets, indicating growing optimism about the stock's potential.
